PE20211199A1 - USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY - Google Patents

USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY

Info

Publication number
PE20211199A1
PE20211199A1 PE2021000514A PE2021000514A PE20211199A1 PE 20211199 A1 PE20211199 A1 PE 20211199A1 PE 2021000514 A PE2021000514 A PE 2021000514A PE 2021000514 A PE2021000514 A PE 2021000514A PE 20211199 A1 PE20211199 A1 PE 20211199A1
Authority
PE
Peru
Prior art keywords
reboxetin
narcolepsy
treatment
refers
pharmaceutical composition
Prior art date
Application number
PE2021000514A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of PE20211199A1 publication Critical patent/PE20211199A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Abstract

SE REFIERE A UN KIT QUE COMPRENDE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE REBOXETINA EN UNA CANTIDAD DE 10 MG E INSTRUCCIONES DE USO DE LA COMPOSICION FARMACEUTICA. TAMBIEN SE REFIERE AL USO DE REBOXETINA PARA EL TRATAMIENTO DE LA NARCOLEPSIA CON CATAPLEXIA, QUE COMPRENDE ADMINISTRAR REBOXETINA A UN HUMANO QUE LO NECESITA, EN DONDE LA REBOXETINA SE ADMINISTRA AL MENOS UNA VEZ AL DIA DURANTE AL MENOS TRES SEMANAS.REFERS TO A KIT INCLUDING A PHARMACEUTICAL COMPOSITION INCLUDING REBOXETIN IN A QUANTITY OF 10 MG AND INSTRUCTIONS FOR USE OF THE PHARMACEUTICAL COMPOSITION. IT ALSO REFERS TO THE USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY WITH CATAPLEXIA, WHICH INCLUDES ADMINISTERING REBOXETIN TO A HUMAN IN NEED OF IT, WHERE REBOXETIN IS ADMINISTERED AT LEAST ONCE A DAY FOR AT LEAST THREE.

PE2021000514A 2018-10-15 2019-10-14 USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY PE20211199A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745956P 2018-10-15 2018-10-15
PCT/US2019/056134 WO2020081461A1 (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Publications (1)

Publication Number Publication Date
PE20211199A1 true PE20211199A1 (en) 2021-07-01

Family

ID=70284075

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000514A PE20211199A1 (en) 2018-10-15 2019-10-14 USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY

Country Status (16)

Country Link
EP (1) EP3866768A4 (en)
JP (1) JP2022504975A (en)
KR (1) KR20210071046A (en)
CN (1) CN112888430A (en)
AU (2) AU2019361915A1 (en)
BR (1) BR112021007019A2 (en)
CA (1) CA3115983A1 (en)
CL (1) CL2021000924A1 (en)
CO (1) CO2021004681A2 (en)
CR (1) CR20210514A (en)
EC (1) ECSP21031200A (en)
IL (1) IL282311A (en)
MX (1) MX2021004207A (en)
PE (1) PE20211199A1 (en)
SG (1) SG11202103588WA (en)
WO (1) WO2020081461A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20230055668A (en) * 2021-10-19 2023-04-26 단국대학교 천안캠퍼스 산학협력단 Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
EP1763354A2 (en) * 2004-06-09 2007-03-21 Pfizer Limited Use of reboxetine for the treatment of pain
CA2905457A1 (en) * 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy

Also Published As

Publication number Publication date
IL282311A (en) 2021-05-31
CN112888430A (en) 2021-06-01
CR20210514A (en) 2021-11-12
AU2023200917A1 (en) 2023-03-23
WO2020081461A1 (en) 2020-04-23
SG11202103588WA (en) 2021-05-28
CA3115983A1 (en) 2020-04-23
KR20210071046A (en) 2021-06-15
MX2021004207A (en) 2021-08-11
AU2019361915A1 (en) 2021-05-13
BR112021007019A2 (en) 2021-07-13
EP3866768A1 (en) 2021-08-25
JP2022504975A (en) 2022-01-13
CL2021000924A1 (en) 2021-09-03
CO2021004681A2 (en) 2021-06-21
ECSP21031200A (en) 2021-05-31
EP3866768A4 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
CO2022002685A2 (en) Enhanced Lipid Nanoparticles for Nucleic Acid Delivery
PE20211199A1 (en) USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY
CO2021000174A2 (en) Topical compositions for pain relief
NI200800169A (en) USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF PAIN
CY1123398T1 (en) COMBINATION COMPOSITION
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
BR112015026247A8 (en) compound in combination with a cytidine analogue, pharmaceutical composition comprising them, use thereof and kit
AR111374A1 (en) USE OF LIK066 IN PATIENTS WITH HEART FAILURE
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
CO2017007874A2 (en) Compositions and methods for improved muscle metabolism
ES2525009T3 (en) Glycoproteins that have lipid mobilization properties and therapeutic uses thereof
AR103118A1 (en) ANAMORELINE-BASED MEDICAL TREATMENTS
AR048806A1 (en) USE OF CARIOFILENES IN THE PREPARATION OF MEDICINES AND TREATMENT OF BODY INFLAMMATION AND INFLAMMATORY PAIN AFFECTIONS
CL2008001477A1 (en) Pharmaceutical composition composed of the synergistic combination of an anticonvulsant agent such as gabapentin and a non-steroidal anti-inflammatory agent such as meloxicam, the concentration ranges present for gabapentin are 3 to 300 mg and 0.1 to 30 mg for meloxicam; and use to treat neuropathic pain
AR065139A1 (en) MEDICATION FOR THE TREATMENT OF ENDOMETRIOSIS
MY193963A (en) Composition for treating joint diseases and kit containing same
CO6470875A2 (en) A COMPOSITE TO USE IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
CL2010001594A1 (en) Use of nifurtimox to prepare a medicine useful in the treatment of diseases caused by trichomonadide.
CO2023009085A2 (en) Levodopa dosage regimen
CL2022001079A1 (en) Methods and compositions for the treatment of rett syndrome
AR048068A1 (en) PIPERAZINAS DERIVED FROM UREA FOR THE TREATMENT OF ENDOMETRIOSIS
AR047154A1 (en) TREATMENT OF INSOMNIA IN HUMAN PATIENTS ADMINISTRANDOLES A DAILY AMOUNT OF GABOXADOL
AR061046A1 (en) MIRTAZAPINE FOR THE TREATMENT OF NEUROPATHIC PAIN
BRPI0509305A (en) use of an insulin sensitizer, pharmaceutical composition, and kit